Shannon Langmead, MSN, CRNP, CNRN, RN (Johns Hopkins)
Download Bio
Download Presentation
Evaluation Card
Chuck began his career working in production and hyping up hopeful contestants on CBS’ The Price is Right with Bob Barker. His infectious personality and energy have enabled Chuck to become one of the top network television audience warm-up hosts in the country. He’s opened for such shows as Dancing with the Stars, American Idol, The Masked Singer, America's Got Talent and The Voice. He served as host of a reality cooking show “Battle of the Chefs” on the Chef Life Network and has been an on-air correspondent for Lucasfilm for the two most recent Star Wars Celebrations. Along with a very busy television schedule, Chuck can be found working with hundreds of nonprofits and organizations across the country as an MC and a benefit charity auctioneer, using energy and skill to bark out bids and raise millions of dollars yearly for organizations like Dunkin Donuts’ Joy Foundation, Stand Up to Cancer, American Cancer Society, and countless philanthropic causes.
Laura J. Zitella, MS, RN, ACNP-BC, AOCN, FAPO
Nurse Practitioner
Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program
Associate Clinical Professor
University of California, San Francisco
San Francisco, CA
Laura J. Zitella, MS, RN, ACNP-BC, AOCN ® , is a nurse practitioner in the Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program and Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science
from the University of Illinois in Chicago. Laura holds certifications as an Acute Care Nurse Practitioner, an Advanced Oncology Certified Nurse, and is an APSHO Fellow of Advanced Practice in Oncology. Her clinical expertise focuses on the management of patients with lymphoma and myeloma. She is deeply committed to providing evidence-based, patient-centered care and to supporting the professional growth of nurses and advanced practice providers through teaching and mentorship.
Learning Objectives:
- Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with multiple myeloma
- Identify patients with multiple myeloma who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific antibodies
- Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma
- Educate patients with myeloma and their caregivers on how to identify and mitigate risk and thereby improve outcomes
Download Bio
Download Presentation
Evaluation Card
Download Bio
Download Presentation
Download Handout
Kimberly Posada, MSN, BSN, NP-C, CNS is an oncology nurse practitioner at the Comprehensive Breast Health Center at UC San Diego Health. She has worked in oncology for more than 24 years, with expertise in breast cancer outpatient treatment, symptom management, DCIS, and survivorship. She earned her dual Master of Science in Nursing degree as an Oncology Advanced Practice Nurse and Clinical Nurse Specialist from the University of California, Los Angeles, and her Bachelor of Science in Nursing from the University of Washington. She is a member of the Oncology Nursing Society, San Diego Advanced Practice Oncology Providers, and the Advanced Practitioner Society for Hematology and Oncology, and is board-certified by the American Association of Nurse Practitioners.
- Learning Objectives:
- Collaborate with multidisciplinary colleagues to identify each patient with HR-positive / HER2-negative EBC who is eligible for CDK4/6 inhibitor treatment
- Recommend the optimal CDK4/6 inhibitor treatment for each patient with HR-positive / HER2-negative EBC in alignment with NCCN Guidelines, high-level evidence, and expert-recommended best practices
- Support open and frequent patient-clinician communication to enable effective counseling on the treatment benefits versus potential risks of adjuvant CDK4/6 inhibitor treatment, reporting of patient-felt toxicities, and screening for barriers to adherence / persistence
- Implement proactive toxicity monitoring, dose modification, and supportive care to enable patient adherence and persistence to CDK4/6 inhibitor treatment for HR-positive / HER2-negative EBC
Stephany Rodriguez, RN, MS, NP
Hematology, Oncology, Blood and Marrow Transplant and Cellular Therapy (HBC)
Clinical Site Coordinator, Oncology APP Fellowship Program
University of California, San Francisco
Stephany Rodriguez is a Nurse Practitioner in the department of Hematology Oncology Blood and Marrow Transplant and Cellular Therapy at UCSF. She has been working with patients with blood cancers for almost 25 years. She is particularly dedicated to the care of patients with leukemias and those undergoing hematopoietic stem cell transplant. She is also passionate about RN and APP education. She is the director of UCSF’s Cancer Services APP fellowship for newly graduated APPs.
Learning Objectives:
- Support shared decision-making by educating patients with CP-CML about the latest clinical evidence and regulatory approvals for TKIs that are most likely to meet their treatment goals
- Identify patients with CP-CML at risk for suboptimal adherence/persistence to their TKI therapy
- Apply evidence-based strategies for supportive care and dose optimization to manage TKI-related adverse events in patients with CP-CML
Chuck Dukas
OCS 2025 Master of Ceremonies and Host
Laura J. Zitella, MS, RN, ACNP-BC, AOCN, FAPO (UCSF)
Download Bio
Download Presentation
Evaluation
Stephany Rodriguez, RN, MS, NP (UCSF)
Program Description:
Oncology nurses play a pivotal role in managing relapsed/refractory multiple myeloma (RRMM), where disease progression is shaped by biologic complexity, treatment resistance, and disparities in access to care. As frontline providers, nurses have helped guide the use of modern standards of care, including bispecific antibodies and CAR T-cell therapy, and are now poised to incorporate emerging therapies—such as cereblon E3 ligase modulators (CELMoDs)—as the latest immune-stimulating option.
This NCPD-certified presentation is designed to equip nurses with practical insights on integrating CELMoDs into RRMM care. Through expert-led discussions, participants will strengthen their ability to educate patients, support shared decision-making, and address real-world dosing, safety, and therapy delivery considerations. Join the nurse experts live and learn how to MoDernize your practice!
Learning Objectives:
Upon completion of this activity, participants should be better able to:
Cite evidence supporting a clinical role for newer mechanisms, such as cereblon E3 ligase modulatory drugs (CELMoDs), as part of sequential therapy for relapsed/refractory multiple myeloma (RRMM)
Educate patients with MM about therapeutic expectations with CELMoD-based regimens, including efficacy, safety, and access to treatment
Prepare nurse-led, team-based protocols to address delivery-of-care considerations with CELMoDs, including coordination of trial enrollment and management of adverse events
Tiffany A. Richards, PhD, ANP-BC, AOCNP (University of Texas MD Anderson)
Shannon Langmead is an Adult Nurse Practitioner and Clinic Coordinator for The Johns Hopkins Comprehensive Neurofibromatosis Center in Baltimore, Maryland. Ms. Langmead completed her undergraduate studies at Saint Francis University in Loretto, Pennsylvania and Villa Julie College in Stevenson, Maryland where she received a BA in Spanish and BS in Nursing. She worked as a bedside nurse in Neurology and Neurosurgery at Johns Hopkins Hospital in Baltimore, Maryland for 8 years before completing her Master of Science Degree in Nursing at Johns Hopkins University School of Nursing and joining the Johns Hopkins Neurofibromatosis team. Ms. Langmead has also worked as Part-time Clinical Faculty for Johns Hopkins University School of Nursing and volunteered with Brainy Camps. She is a Board-Certified Adult Nurse Practitioner. Ms. Langmead evaluates and manages patients with neurofibromatosis type 1 (NF1) and schwannomatosis. Special interests include pain management and developing social support networks for patients.
Learning Objectives
1. Integrate NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs and informed treatment decision-making discussions with patients
2. Incorporate MEK inhibitors in the management of NF1-PNs in adult and pediatric patients by supporting evidence-based monitoring, safety management, and clinician-led treatment decision-making
3. Develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and supports individualized, longitudinal management
Download Bio
Download Presentation
Posttest/Evaluation
Teresa Knoop is an Assistant Director of the Clinical Trials Shared Resource at the Vanderbilt-Ingram Cancer Center in Nashville, TN. She graduated from Murray State University in Murray,KY with a BSN and earned her Master’s Degree in Nursing from the Vanderbilt University School of Nursing. Teresa is an Advanced Oncology Certified Nurse through the Oncology Nursing Society and is a Certified Clinical Research Professional through the Society of Clinical Research Associates. She has published articles in nursing journals and speaks frequently on the topics of molecularly targeted cancer therapies and cancer clinical trials.
Download Bio
Download Presentation
Posttest/Evaluation
Karen Reckamp MD, FASCO, Director, Division of Medical Oncology (Cedars-Sinai)
Michael Mauro is Attending Physician, Professor of Medicine, Director, Chronic Myeloid Leukemia Program, and Member, Memorial Sloan Kettering Cancer Center, in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13
years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. His research interests are development of novel agents for CML, increasing the option of treatment free remission
(TFR) / functional cure in CML and identification and management of tyrosine kinase inhibitor related adverse events, specifically cardiovascular events. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.
Karen Reckamp, MD, FASCO, is the Director of the Division of Medical Oncology and a Professor in the Department of Medicine at Cedars-Sinai Medical Center. In addition, she serves as the Associate Director of Clinical Research at the Samuel Oschin Comprehensive Cancer Institute. Dr. Reckamp specializes in the treatment of lung cancer, with research focusing on biomarker discovery and targeted therapy development. She leads phase 1, 2, and 3 trials evaluating novel treatment approaches in thoracic oncology.
Learning objectives:
• Describe the role of HER2 alterations in NSCLC and the distinctions among HER2 mutation, amplification, and overexpression
• Differentiate HER2-targeted therapy classes by mechanism, administration, and toxicity patterns relevant to nursing care of patients with NSCLC
• Assess patient-specific factors to support personalized treatment planning in HER2- mutant NSCLC
• Implement practical nursing strategies to improve testing coordination, symptom monitoring, and patient adherence for individuals with HER2-mutant NSCLC within one’s practice setting
Kimberly Posada, MSN, BSN, NP-C, CNS (UC San Diego)
Copyright 2024 GLAONS All rights reserved.
Kristy Rostocil, AGACNP-BC is a board-certified Adult-Gerontology Acute Care Nurse Practitioner specializing in gastrointestinal (GI) oncology at Seidman Cancer Center in Cleveland, Ohio. With more than 12 years of combined experience as a registered nurse and nurse practitioner, she is dedicated to providing compassionate, evidence-based care to patients with gastrointestinal cancers. Kristy earned her degree from Kent State University and is committed to advancing oncology care through clinical excellence and patient education.
Learning Objectives:
- Summarize the relevance of recent, practice‑changing clinical evidence on HER2‑targeted therapies for patients with HER2‑positive GEA and BTC to current nursing practice
- Implement evidence‑based strategies for assessing, preventing, and managing toxicities associated with HER2‑targeted therapies used in the treatment of HER2‑positive GEA and BTC
- Employ effective communication techniques and patient‑education tools to counsel patients with HER2‑positive GEA and BTC on the benefits, risks, and expectations of HER2‑targeted treatment, and to facilitate coordinated care within the multidisciplinary team
Nikka Berkowitz, AGACNP- BC, OCN®,
Kristy Rostocil, AGACNP-BC (UH Seidman)
PRESENTERS
Click on each link below for a printable file.
Teresa Knoop, MSN, RN, AOCN-Emeritus (emerita Vanderbilt)
Nikka Berkowitz, AGACNP- BC, OCN®, is an Oncology Nurse Practitioner at Cedars-Sinai Medical Center. She specializes in the treatment of thoracic and urologic malignancies and has more than 15 years of experience in oncology. In her role at Cedars-Sinai, Ms. Berkowitz collaborates with the multidisciplinary team to manage treatment, supportive care, and surveillance plans across a panel of over 500 patients.
Learning objectives:
• Describe the role of HER2 alterations in NSCLC and the distinctions among HER2 mutation, amplification, and overexpression
•Differentiate HER2-targeted therapy classes by mechanism, administration, and toxicity patterns relevant to nursing care of patients with NSCLC
• Assess patient-specific factors to support personalized treatment planning in HER2- mutant NSCLC
• Implement practical nursing strategies to improve testing coordination, symptom monitoring, and patient adherence for individuals with HER2-mutant NSCLC within one’s practice setting